Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Steroidogenesis Inhibitors (STGI) -- Ignore unavailable to you. Want to Upgrade?

To: Jim Burnham who wrote (59)	3/30/1999 9:01:00 AM
From: Jim Burnham	Read Replies (1) \| Respond to of 294

Steroidogenesis -STGI- Announces Georgetown University Study Using Anticort in Attempt to Prevent Retinitis Pigmentosa -RP- in Mice LAS VEGAS--(BW HealthWire)--March 30, 1999--Steroidogenesis Inhibitors International (OTCBB:STGI) reports that Georgetown University's study using Anticort(TM), an anticortisol/Steroidogenesis inhibitor drug, in an attempt to prevent retinitis pigmentosa in transgenic mice began Monday, March 29,1999. Results of the study, expected in less than six months, should provide potential clues for the prevention and eventual treatment of retinitis pigmentosa, a disease leading to blindness with no known treatment. The transgenic mice, are mice that through a genetic manipulation develop within a four week period a destructive condition of the retina, resembling retinitis pigmentosa. ANTICORT(TM) will be administered to successive litters of mice, to ascertain if this form of RP can either be prevented, reduced or stopped altogether. The use of ANTICORT(TM) is based upon its anticortisol activity, intended, among others, to protect retinal degeneration from the potential destructive effect of corticosteriods manufactured in the retina itself, as demonstrated by the Georgetown University Group. Retinitis Pigmentosa (RP) is a term encompassing a group of hereditary retinal degenerations, evolving from night blindness in adolescence to progressive loss of peripheral or central vision after the age of 50, i.e. central or peripheral blindness. In the U.S.. there are about 300,000 people suffering various forms of RP. This release may include "forward-looking statement" within the meaning of section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1034. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable it can give no assurance that such expectations will prove correct. This is neither an offer to buy or sell a security. For informational purposes only, from sources deemed to be reliable. For more information visit our World Wide Web page at www.anticort.com. CONTACT: Steroidogenesis, Las Vegas Janet Greeson, Ph.D., 702/735-7001 or Georgetown University Office of External Affairs Ms. Nancy Whelan, 202/687-4704 or H.L. Lanzet Inc., New York Herbert Lanzet or DeeDee Lanzet, 212/687-0061 or Performance Strategies Richard L. Brown or Chuck Jordan, 303/471-5943